Magnetization transfer imaging to monitor the evolution of MS

Objectives: To assess the sensitivities of magnetization transfer imaging (MTI)-derived measures in detecting changes over time of macro- and microscopic lesion burdens in different MS phenotypes and to compare them with those of T2-weighted and T1-weighted lesion volumes. Methods: A total of 96 patients were studied: 39 with relapsing-remitting MS (RRMS), 19 with secondary progressive MS (SPMS), nine with primary progressive MS, and nine with benign MS; 20 with clinically isolated syndromes suggestive of MS at presentation; and 20 healthy subjects. Brain T2-weighted, T1-weighted, and MTI scans were obtained at baseline and after 12 months. The authors measured T2-weighted and T1-weighted lesion volumes and average lesion MT ratio (MTR). The authors also derived MTR histograms from whole brain tissue (WBT) and normal-appearing brain tissue (NABT). Results: In healthy control subjects, there was no significant change of any of the MTR histogram parameters. At follow-up, in the entire patient group, T2-weighted lesion volume significantly increased and average lesion MTR, WBT-MTR, NABT-MTR, and histogram peak positions significantly decreased. Patients with RRMS and SPMS had significantly higher changes in T2-weighted lesion volume and all the MTI-derived metrics compared with the other subgroups. MTI changes were more prominent (and significantly different) in patients with SPMS than in those with RRMS. Compared with patients with benign MS, patients with RRMS had significantly greater changes in T2-weighted lesion volume and WBT- and NABT-MTR metrics. Compared with patients with SPMS, patients with primary progressive MS had similar changes of T1-weighted and T2-weighted lesion volumes, but significantly lower changes of MTI-derived measures. Conclusions: MTI-derived measures are sensitive for detecting MS-related changes and might provide valuable outcome measures when assessing treatment effects in clinical trials of patients with MS.

[1]  M Filippi,et al.  Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI , 1999, Neurology.

[2]  W. Mcdonald,et al.  The pathological evolution of multiple sclerosis , 1992, Neuropathology and applied neurobiology.

[3]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[4]  E. Paulesu,et al.  A multiparametric MRI study of frontal lobe dementia in multiple sclerosis , 1999, Journal of the Neurological Sciences.

[5]  F. Barkhof,et al.  Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. , 1993, Brain : a journal of neurology.

[6]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[7]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[8]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[9]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[10]  Massimo Filippi,et al.  Brain and spinal cord MR in benign multiple sclerosis: a follow-up study , 1996, Journal of the Neurological Sciences.

[11]  J K Udupa,et al.  Correlation of volumetric magnetization transfer imaging with clinical data in MS , 1998, Neurology.

[12]  M Filippi,et al.  A magnetization transfer histogram study of normal-appearing brain tissue in MS , 2000, Neurology.

[13]  M Filippi,et al.  Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques , 1999, Multiple sclerosis.

[14]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[15]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[16]  D. Miller,et al.  Magnetic resonance in monitoring the treatment of multiple sclerosis , 1994, Annals of neurology.

[17]  W. I. McDonald,et al.  Heterogeneity of blood‐brain barrier changes in multiple sclerosis , 1990, Neurology.

[18]  M Rovaris,et al.  Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis , 1998, Neurology.

[19]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[20]  M Cercignani,et al.  Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers. , 2000, AJNR. American journal of neuroradiology.

[21]  R I Grossman,et al.  Quantitative volumetric magnetization transfer analysis in multiple sclerosis: Estimation of macroscopic and microscopic disease burden , 1996, Magnetic resonance in medicine.

[22]  F. Barkhof,et al.  Primary and transitional progressive MS , 1999, Neurology.

[23]  P. C. de Freitas Mathias,et al.  Insulin Secretion and Acetylcholinesterase Activity in Monosodium L-Glutamate-Induced Obese Mice , 2001, Hormone Research in Paediatrics.

[24]  R I Grossman,et al.  Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. , 1995, Radiology.

[25]  M Rovaris,et al.  Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis. , 1999, AJNR. American journal of neuroradiology.

[26]  Ludwig Kappos,et al.  Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials , 1997, Journal of Neurology.

[27]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[28]  T Locatelli,et al.  Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[29]  A. Thompson,et al.  Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[30]  G. Barker,et al.  Correlation of magnetization transfer ration with clinical disability in multiple sclerosis , 1994, Annals of neurology.

[31]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[32]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[33]  M Filippi,et al.  A Magnetization Transfer Imaging Study of Normal-Appearing White Matter in Multiple Sclerosis , 1995, Neurology.

[34]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[35]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[36]  F. Barkhof,et al.  The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis , 1999, Neurology.

[37]  G. Barker,et al.  Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis , 1999, Multiple sclerosis.